CDK4 and neoplasm: For example, ER-negative patients with low cytoplasmic NUB1 (mean IPS = 1.1% vs. 60.0%) in high-cytoplasmic NUB1 tumours may benefit from alternative regimens, such as CDK4/6 inhibitors, to bypass defective cell cycle checkpoints [40].